Dual neonate vaccine platform against HIV-1 and M. tuberculosis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Hopkins, Richard ^a   Bridgeman, Anne ^a   Joseph, Joan ^b   Gilbert, Sarah C ^c   McShane, Helen ^c   Hanke, Tomáš ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; FEMALE; GENETIC TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; NEWBORN CARE; NONHUMAN; PROMOTER REGION; TRANSGENE; TUBERCULOSIS; VACCINE PRODUCTION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; AFRICA; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; GENETICS; HUMAN; IMMUNOLOGY; INFANT; SYNTHESIS; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS ANKARA;

AFRICA; AIDS VACCINES; ANIMALS; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PROMOTER REGIONS, GENETIC; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TRANSGENES; TUBERCULOSIS VACCINES;

EID: 79955939284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020067     Document Type: Article

References (59)

1. WHO (2009) 2009 AIDS epidemic update. WHO Report pp. 1-100.
2. Safrit JT, Ruprecht R, Ferrantelli F, Xu W, Kitabwalla M, et al. (2004) Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 35: 169-177.
3. Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, et al. (2009) Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 83: 5505-5513.
4. Lugosi L, Jacobs W, Bloom BR, (1989) Transformation of BCG with plasmid DNA. Acta Leprol 7 (Suppl 1): 256-257.
5. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456-460.
6. Sun R, Skeiky YAW, Izzo A, Dheenadhayalan V, Imam Z, et al. (2009) Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27: 4412-4423.
7. Yasutomi Y, Koenig S, Haun SS, Stover CK, Jackson RK, et al. (1993) Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 150: 3101-3107.
8. Im EJ, Saubi N, Virgili G, Sander C, Teoh D, et al. (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 81: 9408-9418.
9. Wu X, Yang ZY, Li Y, Hoperkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
10. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L, (2007) Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol 88: 1-12.
11. Hanke T, McMichael AJ, (2000) Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6: 951-955.
12. EDCTPhttp://www.edctp.org/.
13. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271: 698-702.
14. Rodrigues LC, Diwan VK, Wheeler JG, (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22: 1154-1158.
15. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
16. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, et al. (2009) Safety and Immunogenicity of a New TB Vaccine, MVA85A, in M. tuberculosis Infected Individuals. Am J Respir Crit Care Med.
17. Whelan KT, Pathan AA, Sander CR, Fletcher HA, Poulton I, et al. (2009) Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE 4: e5934.
18. de Cassan SC, Pathan AA, Sander CR, Minassian A, Rowland R, et al. Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin Vaccine Immunol 17: 1066-1073.
19. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40: 279-290.
20. Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, et al. (2010) Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol 84: 5898-5908.
21. Wang Z, Martinez J, Zhou W, La Rosa C, Srivastava T, et al. (2010) Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 28: 1547-1557.
22. Wyatt LS, Shors ST, Murphy BR, Moss B, (1996) Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14: 1451-1458.
23. Hanke T, Szawlowski P, Randall RE, (1992) Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. J Gen Virol 73: 653-660.
24. Nkolola JP, Wee EG-T, Im E-J, Jewell CP, Chen N, et al. (2004) Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 11: 1068-1080.
25. Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, et al. (2010) Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. Journal of virology 84: 5898-5908.
26. Im E-J, Saubi N, Virgili G, Sander C, Teoh D, et al. (2007) Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. Journal of virology 81: 9408-9418.
27. Im E-J, Hanke T, (2004) MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3: S89-97.
28. McShane H, Hill A, (2005) Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7: 962-967.
29. Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, et al. (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113: 259-266.
30. Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, et al. (2006) Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 74: 2706-2716.
31. Dasgupta A, Hammarlund E, Slifka MK, Fruh K, (2007) Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J Immunol 178: 1654-1661.
32. Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, et al. (2007) Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204: 2187-2198.
33. Li P, Wang N, Zhou D, Yee CS, Chang CH, et al. (2005) Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J Immunol 175: 6481-6488.
34. Liu L, Chavan R, Feinberg M, (2008) Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC immunology 9: 15.
35. Rehm KE, Connor RF, Jones GJ, Yimbu K, Mannie MD, et al. (2009) Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II. Immunology 128: 381-392.
36. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, et al. (1988) Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 168: 1211-1224.
37. Webb TJ, Litavecz RA, Khan MA, Du W, Gervay-Hague J, et al. (2006) Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur J Immunol 36: 2595-2600.
38. Létourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2: e984.
39. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
40. Chakrabarti S, Sisler JR, Moss B, (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23: 1094-1097.
41. Earl PL, Cotter C, Moss B, Vancott T, Currier J, et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27: 5885-5895.
42. Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, et al. (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25: 1969-1992.
43. Wang Z, La Rosa C, Li Z, Ly H, Krishnan A, et al. (2007) Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25: 1132-1141.
44. Chen Z, Huang Y, Zhao X, Ba L, Zhang W, et al. (2008) Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B′. J Acquir Immune Defic Syndr 47: 412-421.
45. Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, et al. (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. Journal of virology 83: 7176-7184.
46. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, et al. (2005) Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 79: 12871-12879.
47. Chege GK, Thomas R, Shephard EG, Meyers A, Bourn W, et al. (2009) A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 27: 4857-4866.
48. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, et al. (2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4: e5264.
49. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, et al. (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77: 3364-3373.
50. Bridgeman A, Roshorm Y, Lockett LJ, Xu ZZ, Hopkins R, et al. (2010) Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28: 474-483.
51. Rosario M, Fulkerson J, Soneji S, Parker J, Im EJ, et al. (2010) Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol 84: 7815-7821.
52. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, et al. (2008) Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 12: 1376-1379.
53. Pavelka MS Jr, Jacobs WR Jr, (1999) Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J Bacteriol 181: 4780-4789.
54. Joseph J, Fernandez-Lloris R, Pezzat E, Saubi N, Cardona PJ, et al. Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors. J Biomed Biotechnol 2010: 357370.
55. Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2: e984.
56. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, et al. (1988) An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85: 3105-3109.
57. McShane H, Brookes R, Gilbert SC, Hill AV, (2001) Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69: 681-686.
58. Bridgeman A, Roshorm Y, Lockett LJ, Xu Z-Z, Hopkins R, et al. (2009) Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 28: 474-483.
59. Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, et al. (2004) The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. Journal of Immunological Methods 285: 25-40.